These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 14725579)

  • 1. Review article: screening and surveillance of Barrett's oesophagus: what is a cost-effective framework?
    Spechler SJ; Barr H
    Aliment Pharmacol Ther; 2004 Feb; 19 Suppl 1():49-53. PubMed ID: 14725579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barrett's oesophagus: optimal strategies for prevention and treatment.
    Fass R; Sampliner RE
    Drugs; 2003; 63(6):555-64. PubMed ID: 12656653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Surveillance for Barrett's oesophagus: worthwhile?].
    Kastelein F; Kuipers EJ
    Ned Tijdschr Geneeskd; 2012; 156(49):A5497. PubMed ID: 23218039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barrett's oesophagus: Current controversies.
    Amadi C; Gatenby P
    World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma.
    Sonnenberg A; Soni A; Sampliner RE
    Aliment Pharmacol Ther; 2002 Jan; 16(1):41-50. PubMed ID: 11856077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrett's oesophagus: a review of costs of the illness.
    Arguedas MR; Eloubeidi MA
    Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus.
    Inadomi JM
    Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):51-63. PubMed ID: 25743456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
    Armstrong D
    Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should patients with Barrett's oesophagus be kept under surveillance? The case against.
    Barritt AS; Shaheen NJ
    Best Pract Res Clin Gastroenterol; 2008; 22(4):741-50. PubMed ID: 18656827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barrett's oesophagus: epidemiology, diagnosis and clinical management.
    Whiteman DC; Kendall BJ
    Med J Aust; 2016 Oct; 205(7):317-24. PubMed ID: 27681974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A surveillance programme for Barrett's oesophagus in a UK general hospital.
    Olithselvan A; Gorard DA; McIntyre AS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Barrett esophagus. Current situation of the risk and surveillance policy].
    Robaszkiewicz M
    Presse Med; 1994 Dec; 23(40):1846-8. PubMed ID: 7899314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are screening and surveillance for Barrett's oesophagus really worthwhile?
    Sharma P; Sidorenko EI
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation.
    Morris CD; Byrne JP; Armstrong GR; Attwood SE
    Br J Surg; 2001 Oct; 88(10):1357-62. PubMed ID: 11578292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?
    Inadomi JM; Saxena N
    Dig Dis Sci; 2018 Aug; 63(8):2094-2104. PubMed ID: 29948571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rationale for screening and surveillance of Barrett's metaplasia.
    Wani S; Sharma P
    Best Pract Res Clin Gastroenterol; 2006; 20(5):829-42. PubMed ID: 16997164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer.
    Streitz JM; Ellis FH; Tilden RL; Erickson RV
    Am J Gastroenterol; 1998 Jun; 93(6):911-5. PubMed ID: 9647017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening and surveillance for complications related to gastroesophageal reflux disease.
    Spechler SJ
    Am J Med; 2001 Dec; 111 Suppl 8A():130S-136S. PubMed ID: 11749938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.